WO2001040279A3 - Hbv sequences - Google Patents

Hbv sequences Download PDF

Info

Publication number
WO2001040279A3
WO2001040279A3 PCT/EP2000/011526 EP0011526W WO0140279A3 WO 2001040279 A3 WO2001040279 A3 WO 2001040279A3 EP 0011526 W EP0011526 W EP 0011526W WO 0140279 A3 WO0140279 A3 WO 0140279A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
genotype
polypeptides
hbv
acid sequence
Prior art date
Application number
PCT/EP2000/011526
Other languages
French (fr)
Other versions
WO2001040279A2 (en
Inventor
Lieven Stuyver
Geyt Caroline Van
Gendt Sija De
Original Assignee
Innogenetics Nv
Lieven Stuyver
Geyt Caroline Van
Gendt Sija De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99870252A external-priority patent/EP1104811A1/en
Application filed by Innogenetics Nv, Lieven Stuyver, Geyt Caroline Van, Gendt Sija De filed Critical Innogenetics Nv
Priority to CA002392853A priority Critical patent/CA2392853A1/en
Priority to AU23582/01A priority patent/AU2358201A/en
Priority to JP2001541034A priority patent/JP2003515327A/en
Priority to EP00987273A priority patent/EP1234040A2/en
Publication of WO2001040279A2 publication Critical patent/WO2001040279A2/en
Publication of WO2001040279A3 publication Critical patent/WO2001040279A3/en
Priority to HK02108309.7A priority patent/HK1048492A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The complete nucleic acid sequence of a new human hepatitis B virus genotype, provisionally named genotype G, is reported. This genotype was found with a high prevalence in patients chronically infected with HBV and residing in Europe and the USA. The present invention further relates to polypeptides encoded by said nucleic acid sequence and to antibodies recognizing said polypeptides. The present invention also relates to the use of said nucleic acid, polypeptides and antibodies in HBV diagnosis, prophylaxis and therapy.
PCT/EP2000/011526 1999-12-03 2000-11-20 Hbv sequences WO2001040279A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002392853A CA2392853A1 (en) 1999-12-03 2000-11-20 Hbv sequences
AU23582/01A AU2358201A (en) 1999-12-03 2000-11-20 New hbv sequences
JP2001541034A JP2003515327A (en) 1999-12-03 2000-11-20 HBV sequence
EP00987273A EP1234040A2 (en) 1999-12-03 2000-11-20 Hbv sequences
HK02108309.7A HK1048492A1 (en) 1999-12-03 2002-11-15 Hbv sequences

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99870252.6 1999-12-03
EP99870252A EP1104811A1 (en) 1999-12-03 1999-12-03 HBV sequences
US16928799P 1999-12-07 1999-12-07
US60/169,287 1999-12-07

Publications (2)

Publication Number Publication Date
WO2001040279A2 WO2001040279A2 (en) 2001-06-07
WO2001040279A3 true WO2001040279A3 (en) 2002-01-10

Family

ID=26153865

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/011526 WO2001040279A2 (en) 1999-12-03 2000-11-20 Hbv sequences

Country Status (6)

Country Link
EP (1) EP1234040A2 (en)
JP (1) JP2003515327A (en)
AU (1) AU2358201A (en)
CA (1) CA2392853A1 (en)
HK (1) HK1048492A1 (en)
WO (1) WO2001040279A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034841B2 (en) 2011-04-21 2015-05-19 Isis Pharmaceuticals, Inc. Modulation of hepatitis B virus (HBV) expression

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2486420C (en) 2002-06-14 2014-04-15 Gen-Probe Incorporated Compositions and methods for detecting hepatitis b virus
AU2003261977A1 (en) 2002-09-06 2004-03-29 Advanced Life Science Institute, Inc. Hbv precore protein capable of forming particles
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
WO2004113370A1 (en) * 2003-06-20 2004-12-29 Dade Behring Marburg Gmbh Novel surface protein (hbsag) variant of hepatitis b virus
US8242238B2 (en) 2003-06-20 2012-08-14 Dade Behring Marburg Gmbh Surface protein (HBsAg) variant of the hepatitis B virus
DE10339927A1 (en) * 2003-08-29 2005-03-24 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Composition for the prophylaxis / therapy of HBV infections and HBV-mediated diseases
EP2316942B1 (en) * 2004-12-22 2021-04-21 Alnylam Pharmaceuticals, Inc. Conserved hbv and hcv sequences useful for gene silencing
EA028659B1 (en) * 2011-02-12 2017-12-29 Глоубиммьюн, Инк. Yeast-based therapeutic for treating chronic hepatitis b
US9045803B2 (en) 2012-02-29 2015-06-02 Abbott Molecular Inc. Hepatitis B virus typing and resistance assay
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
AR114551A1 (en) 2018-08-13 2020-09-16 Alnylam Pharmaceuticals Inc COMPOSITIONS OF hdRNA AGENTS AGAINST HEPATITIS B VIRUS (HBV) AND METHODS FOR THEIR USE
WO2021060450A1 (en) 2019-09-27 2021-04-01 富士レビオ株式会社 Immunoassay for hepatitis b virus core-related antigen and kit therefor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569237A2 (en) * 1992-05-06 1993-11-10 Gen-Probe Incorporated Nucleic acid amplification oligonucletodies and probes to human hepatitis B virus
US5736334A (en) * 1993-04-12 1998-04-07 Abbott Laboratories Nucleotide sequences and process for amplifying and detection of hepatitis B viral DNA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569237A2 (en) * 1992-05-06 1993-11-10 Gen-Probe Incorporated Nucleic acid amplification oligonucletodies and probes to human hepatitis B virus
US5736334A (en) * 1993-04-12 1998-04-07 Abbott Laboratories Nucleotide sequences and process for amplifying and detection of hepatitis B viral DNA

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. TRAN ET AL.: "Emergence of and takeover by hepatitis B virus (HBV) with rearrangements in the PreS/S and PreC/C genes during chronic HBV infection", J. VIROL., vol. 65, no. 7, 1991, pages 3566 - 3574, XP000914642 *
BHAT ET AL.: "Molecular characterisation of a new variant of hepatitis B virus in a persistently infected homosexual man", HEPATOLOGY, vol. 11, no. 2, 1990, pages 271 - 276, XP000014788 *
H. OHNUMA ET AL.: "Synthetic oligopeptides bearing a common or subtypic determinant of heaptits B surface antigen", J. IMMUNOL., vol. 145, no. 7, 1990, pages 2265 - 2271, XP002044688 *
L. STUYVER AT AL.: "A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness", J. GEN VIROL., vol. 81, no. 1, 2000, pages 67 - 74, XP002177227 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034841B2 (en) 2011-04-21 2015-05-19 Isis Pharmaceuticals, Inc. Modulation of hepatitis B virus (HBV) expression
US9127278B2 (en) 2011-04-21 2015-09-08 Isis Pharmaceuticals, Inc. Modulation of hepatitis B virus (HBV) expression

Also Published As

Publication number Publication date
EP1234040A2 (en) 2002-08-28
CA2392853A1 (en) 2001-06-07
WO2001040279A2 (en) 2001-06-07
AU2358201A (en) 2001-06-12
HK1048492A1 (en) 2003-04-04
JP2003515327A (en) 2003-05-07

Similar Documents

Publication Publication Date Title
WO2001040279A3 (en) Hbv sequences
EP1200109A4 (en) Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
WO2001096353A3 (en) 3'-PRODRUGS OF 2'-DEOXY-β-L-NUCLEOSIDES
CA2158455A1 (en) Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments
WO1996013590A3 (en) New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
BR9911397A (en) Use of hcv envelope protein particles for vaccination
WO2001034809A3 (en) Staphylococcus epidermidis nucleic acids and proteins
WO2002014362A3 (en) A hepatitis c virus non-structural ns3/4a fusion gene
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
WO2007064844A3 (en) Anti-viral griffithsin compounds, compositions, and methods of use
TW200502246A (en) Vaccine
WO2003004627A3 (en) Novel human hepatoma lines, methods for obtaining same and uses thereof
AU2002333773A1 (en) New hepatitis c virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
WO2007031867A3 (en) A hepatitis c virus non-stru tural ns3/4a fusion gene
EP0256677A3 (en) Pseudorabies virus recombinants and their use in the production of proteins
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
WO2001060838A3 (en) Aids ancestral viruses and vaccines
WO2005001029A3 (en) Ancestral viruses and vaccines
WO2000018417A3 (en) Treatment of hepatitis b infection with thymosin alpha 1 and lamivudine
EP1427443A4 (en) Vaccine using papilloma virus e proteins delivered by viral vector
NZ512341A (en) Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
AU2002317474A1 (en) Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof
EP1650225A4 (en) Hetero type pentamer recombinant vaccine
WO2001046696A3 (en) Methods and compositions for detecting hepatitis e virus
WO2000075352A3 (en) Hcv/bvdv chimeric genomes and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000987273

Country of ref document: EP

Ref document number: 2392853

Country of ref document: CA

Ref document number: 23582/01

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2001 541034

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000987273

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000987273

Country of ref document: EP